aspirin has been researched along with Fibrosarcoma in 17 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Fibrosarcoma: A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin given in a lower dose (20 mg/kg) did not show significant difference from the vehicle group." | 5.27 | Reductive effect of aspirin treatment on primary tumor growth and metastasis of implanted fibrosarcoma in rats. ( Hulsman, LO; Kort, WJ; van Schalkwijk, WP; Weijma, IM; Westbroek, DL; Zondervan, PE, 1986) |
| "To examine the effect of a novel phenolic-based compound, 2-hydroxy benzoate zinc (2HBZ), and acetylsalicylic acid (ASA) on human HT-1080 fibrosarcoma cells." | 3.76 | Sub-millimolar concentration of the novel phenol-based compound, 2-hydroxy benzoate zinc, induces apoptosis in human HT-1080 fibrosarcoma cells. ( Alkarrawi, MA; Bowen, ID; Mahdi, AJ; Mahdi, JG; Pepper, CJ, 2010) |
| " In this work, we tested the ability of aspirin to activate the AKT survival pathway in methylcholanthrene-induced fibrosarcoma cells (Meth A) transplanted into BALB/c nude mice and the clinical effect of aspirin cotreatment during etoposide (VP-16)-based anticancer therapy." | 3.73 | Aspirin reduces the outcome of anticancer therapy in Meth A-bearing mice through activation of AKT-glycogen synthase kinase signaling. ( Acquaviva, AM; Acquaviva, F; Di Matola, T; di Palma, A; Leone, V; Matarese, G; Ricchi, P, 2006) |
| "The growth rate (studied by mean tumor dry weight) and vascularization (studied by microangiography) of two transplantable rat tumors, a 20-methylcholanthrene-induced fibrosarcoma and a hepatoma, were significantly reduced by three prostaglandin synthesis inhibitors, indomethacin, diclofenac-sodium and aspirin, irrespective of whether the drugs were administered early or late during tumor growth." | 3.66 | Effects of prostaglandin synthesis inhibitors on tumor growth and vascularization. Experimental studies in the rat. ( Peterson, HI, 1983) |
| "The growth of a 3-methylcholanthrene-induced fibrosarcoma of C3H mice was inhibited by aspirin and indomethacin." | 3.66 | Mechanism of inhibition of tumour growth by aspirin and indomethacin. ( Astoin, M; Castes, M; Lynch, NR; Salomon, JC, 1978) |
| "Aspirin given in a lower dose (20 mg/kg) did not show significant difference from the vehicle group." | 1.27 | Reductive effect of aspirin treatment on primary tumor growth and metastasis of implanted fibrosarcoma in rats. ( Hulsman, LO; Kort, WJ; van Schalkwijk, WP; Weijma, IM; Westbroek, DL; Zondervan, PE, 1986) |
| "aspirin were given daily." | 1.26 | Prostaglandin-mediated hypercalcemia in transitional cell carcinoma of the bladder. ( Gavrell, GJ; Kaplan, RA; Le Blanc, GA; McKay, HA; Meehan, WL, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (76.47) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mahdi, JG | 1 |
| Pepper, CJ | 1 |
| Alkarrawi, MA | 1 |
| Mahdi, AJ | 1 |
| Bowen, ID | 1 |
| di Palma, A | 1 |
| Matarese, G | 1 |
| Leone, V | 1 |
| Di Matola, T | 1 |
| Acquaviva, F | 1 |
| Acquaviva, AM | 1 |
| Ricchi, P | 1 |
| Peterson, HI | 1 |
| Grignani, G | 2 |
| Almasio, P | 2 |
| Pacchiarini, L | 2 |
| Ricetti, MM | 1 |
| Serra, L | 1 |
| Gamba, G | 2 |
| Pagliarino, M | 1 |
| Mahboubi, K | 1 |
| Ferreri, NR | 1 |
| Lynch, NR | 1 |
| Castes, M | 1 |
| Astoin, M | 1 |
| Salomon, JC | 1 |
| McKay, HA | 1 |
| Gavrell, GJ | 1 |
| Meehan, WL | 1 |
| Kaplan, RA | 1 |
| Le Blanc, GA | 1 |
| Valdéz, JC | 1 |
| Perdigón, G | 1 |
| Pillay, DJ | 2 |
| Pope, BL | 2 |
| Karmazyn, M | 1 |
| Kort, WJ | 1 |
| Hulsman, LO | 1 |
| van Schalkwijk, WP | 1 |
| Weijma, IM | 1 |
| Zondervan, PE | 1 |
| Westbroek, DL | 1 |
| Gasic, GJ | 2 |
| Gasic, TB | 2 |
| Murphy, S | 2 |
| Tashjian, AH | 2 |
| Voelkel, EF | 2 |
| Goldhaber, P | 1 |
| Levine, L | 3 |
| Galanti, N | 1 |
| Johnson, T | 1 |
| Hinkle, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for aspirin and Fibrosarcoma
| Article | Year |
|---|---|
Antibodies to pharmacologically active molecules: specificities and some applications of antiprostaglandins.
Topics: Animals; Antibodies; Antibody Specificity; Antigen-Antibody Reactions; Aspirin; Cell Line; Cross Rea | 1973 |
16 other studies available for aspirin and Fibrosarcoma
| Article | Year |
|---|---|
Sub-millimolar concentration of the novel phenol-based compound, 2-hydroxy benzoate zinc, induces apoptosis in human HT-1080 fibrosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; | 2010 |
Aspirin reduces the outcome of anticancer therapy in Meth A-bearing mice through activation of AKT-glycogen synthase kinase signaling.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Aspirin; Etopos | 2006 |
Effects of prostaglandin synthesis inhibitors on tumor growth and vascularization. Experimental studies in the rat.
Topics: Animals; Aspirin; Diclofenac; Fibrosarcoma; Indomethacin; Liver Neoplasms, Experimental; Neoplasm Tr | 1983 |
Interactions between neoplastic cells with different metastasizing capacity and platelet function.
Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Blood Platelets; Cell Line; Cells, Cultured; Culture | 1983 |
Activation of platelet prostaglandin biosynthesis pathway during neoplastic cell-induced platelet aggregation.
Topics: Animals; Apyrase; Aspirin; Blood Platelets; Cell Line; Cell Transformation, Neoplastic; Fibrosarcoma | 1984 |
Production of PGE2 and 15-HETE by fibrosarcoma cells.
Topics: Animals; Arachidonic Acid; Aspirin; Calcimycin; Carbon Radioisotopes; Cell Line; Chromatography, Hig | 1995 |
Mechanism of inhibition of tumour growth by aspirin and indomethacin.
Topics: Animals; Antibodies, Neoplasm; Aspirin; Female; Fibrosarcoma; Hemolytic Plaque Technique; Immunosupp | 1978 |
Prostaglandin-mediated hypercalcemia in transitional cell carcinoma of the bladder.
Topics: Animals; Aspirin; Calcium; Carcinoma, Transitional Cell; Chemical Phenomena; Chemistry; Female; Fibr | 1978 |
Piroxicam, indomethacin and aspirin action on a murine fibrosarcoma. Effects on tumour-associated and peritoneal macrophages.
Topics: Animals; Antigens, Differentiation; Aspirin; Fibrosarcoma; Glucuronidase; Hematocrit; Indomethacin; | 1991 |
Requirement for prostaglandin E1 (PGE1) for the secretion of suppressor cell inducer factors by spleen cells of tumor-bearing mice.
Topics: Alprostadil; Animals; Aspirin; Fibrosarcoma; In Vitro Techniques; Lymphocyte Activation; Male; Mice; | 1986 |
Activation of suppressor cells by low molecular weight factors secreted by spleen cells of tumor-bearing mice: modulatory role of prostaglandins.
Topics: Alprostadil; Animals; Aspirin; Cyclooxygenase Inhibitors; Fibrosarcoma; In Vitro Techniques; Kinetic | 1986 |
Reductive effect of aspirin treatment on primary tumor growth and metastasis of implanted fibrosarcoma in rats.
Topics: Animals; Aspirin; Epoprostenol; Female; Fibrosarcoma; Neoplasm Metastasis; Neoplasm Transplantation; | 1986 |
Anti-metastatic effect of aspirin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Aspirin; Fibrosarcoma; Humans; Mice; Neoplasm Metast | 1972 |
Prostaglandins, calcium metabolism and cancer.
Topics: Animals; Aspirin; Bone and Bones; Bone Resorption; Calcium; Calcium Radioisotopes; Cells, Cultured; | 1974 |
Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease.
Topics: Adenocarcinoma; Animals; Aspirin; Blood Cell Count; Blood Platelets; Carcinoma; Cell Survival; Chrom | 1973 |
Prostaglandin production by mouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin.
Topics: Adrenal Glands; Animals; Antigens; Aspirin; Borohydrides; Clone Cells; Culture Media; Fibroblasts; F | 1972 |